Viral Vector Manufacturing Facility Pty Ltd (VVMF) today announced its participation in the American Society of Gene and Cell Therapy’s annual meeting, taking place 11 – 15 May 2026, in Boston, USA.
Stephen Thompson, Chief Executive Officer, and Vasily Medvedev, Deputy Chief Technology Officer, will be available to discuss the organisation’s expertise across research, process and analytical development, GMP viral vector manufacturing, and the wrap-around services to leverage the advantages of the Australian biotechnology ecosystem.
As Australia’s only viral vector Contract Development and Manufacturing Organisation (CDMO) providing complete life cycle services to the global cell and gene therapy (CGT) sector, VVMF delivers high-quality lentiviral (LV) and adeno-associated viral (AAV) vector solutions tailored to their research, clinical, and commercial needs.
Backed by leading scientific and clinical expertise, VVMF provides a compelling strategic advantage – further strengthened by Australia’s 43.5% R&D tax incentive, which provides a rebate of up to 43.5% for eligible companies.
“With Developers of cell and gene therapies are increasingly looking for manufacturing partners that can support programs across their full lifecycle. At ASGCT, we’re excited to discuss how VVMF works with sponsors to deliver robust, scalable lentiviral and AAV manufacturing solutions — from early clinical development through to commercial readiness — within a globally competitive Australian environment.”
To schedule a meeting contact info@vvmf.com.au
Unlocking the future of medicine